Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

Vitrectomy for macular edema due to retinal vein occlusion | OPTH  Dove Medical Press

Kazuyuki Kumagai,1 Nobuchika Ogino,2 Marie Fukami,1 Mariko Furukawa1 1Kami-iida Daiichi General Hospital, Aichi, Japan; 2Shinjo Ophthalmologic Institute, ...

Grading of macular perfusion in retinal vein occlusion using en-face swept-source optical coherence tomography angiography: A retrospective observational case series  MD Linx

Researchers conducted this retrospective observational case series to assess the effectiveness of swept –source optical coherence tomography angiography ...

The Value of Retinal Vein Occlusion Therapeutics Market Estimated to Soar Higher During 2015 – 2021  PortNews24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 27.5% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article; Related *content*; Metrics; Responses ...

Central Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018 Research Offer by The Market Reports  Industrial Journalism

This report provides top line data relating to the clinical trials on Central Retinal Vein Occlusion. Report includes an overview of trial numbers and their average ...

Retinal Vein Occlusion Therapeutics Market 2025: Deep Analysis of Current Trends and Future Demand by Top Key Players – Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB  thewirenewsnow.com

Retinal Vein Occlusion Therapeutics Market Research Report provides internal and external data and expert surveys in the Retinal Vein Occlusion Therapeutics ...

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?  Yahoo Finance

It has been about a month since the last earnings report for Aerie Pharmaceuticals (AERI). Shares have lost about 10.2% in that time frame, underperforming the ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

Global Retinal Vein Occlusion Therapeutics Market Growth Opportunities concealed in rising Economies 2019- 2025  News Daily

The Retinal Vein Occlusion Therapeutics market report gives an amazing source to survey the Retinal Vein Occlusion Therapeutics market and other basic ...

Retinal Vein Occlusion Pipeline Insight, Overview and Research 2019  Market Trends

“Retinal Vein Occlusion- Pipeline Insight, 2019” report covers the illness review, definition, characterization, side effects, ethology, pathophysiology and ...

Retinal Vein Occlusion Market Clinical Analysis 2016  industryreports24.com

Retinal Vein Occlusion – Market Insight, Epidemiology and Market Forecast – 2028″ report provides a detailed analysis of the Retinal Vein Occlusion ...

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger  Healio

From Retina *Service*, Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania (XG, AO, CMA, FSA, JFV, JH, ACH);and ...

Retinal Vein Occlusion -Synthesis, Epidemiology And Healthcare Experts Reviews 2019-2028  industryreports24.com

Latest Industry Research Report On “Retinal Vein Occlusion – Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Retinal Vein ...

Retinal Vein Occlusion Therapeutics Market: Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2019–2024  Burbank Observer

Retinal Vein Occlusion Therapeutics Market report on title “Global Retinal Vein Occlusion Therapeutics Market 2018 by Manufacturers, Countries, Type and ...

Worldwide Retinal Vein Occlusion Market Pipeline Insight Report (2018 – 2023)  California Oracle

360 MARKET UPDATES Report provides a 360-degree overview of the global Retinal Vein Occlusion Pipeline Insight Market with special emphasis on all ...

Watchmakers trade fair unveils six finalists for its innovation awards  WatchPro

A jury of experts for the 2019 EPHJ-EPMT-SMT Trade Fair has selected six highly innovative projects for the Exhibitors' Grand Prix that covers equipment for ...

Cellectis S.A. (CLLS) and Clearside Biomedical Inc. (NASDAQ:CLSD) Comparison side by side  Stocks Beat

This is a contrast between Cellectis S.A. (NASDAQ:CLLS) and Clearside Biomedical Inc. (NASDAQ:CLSD) based on their institutional ownership, earnings and.

Global Retinal Vein Occlusion Therapeutics Market Professional Survey Report 2018  Honest Version

In this report, the Global Retinal Vein Occlusion Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of ...

Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden  Healio

Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according ...

Global Retinal Vein Occlusion Therapeutics Market Trends 2019: Research Center, Clinic, Hospital  Market Mirror

Global Retinal Vein Occlusion Therapeutics Market research report is an in-depth and a professional document 2019. The Global Retinal Vein Occlusion ...

Retinal Vein Occlusion Therapeutics Market 2019: Development Study by Global Industry Summary, Revenue, Gross Margin and Market Segment by 2024  The Port Bulletin

“Retinal Vein Occlusion Therapeutics Market Analysis, Development and Forecast 2019 – 2024” providing significant insights and providing a competitive ...

Contrasting of Trevi Therapeutics Inc. (TRVI) and Clearside Biomedical Inc. (NASDAQ:CLSD)  Stocks Beat

This is therefore a comparing of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in Trevi Therapeutics ...

OHR Pharmaceutical Inc. (OHRP) and Oragenics Inc. (NYSEAMERICAN:OGEN) Comparison side by side  Stocks Beat

OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Oragenics Inc. (NYSEAMERICAN:OGEN) have been rivals in the Biotechnology for quite some time. Below is a ...

Comparison of Fortress Biotech Inc. (FBIO) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Stocks Beat

Fortress Biotech Inc. (NASDAQ:FBIO) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) compete with each other in the Biotechnology sector. We will ...

Genprex Inc. (GNPX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS)  Stocks Beat

As Biotechnology businesses, Genprex Inc. (NASDAQ:GNPX) and Coherus BioSciences Inc. (NASDAQ:CHRS), are affected by contrast. This especially applies ...

Retinal Vein Occlusion Therapeutics Market Outlook 2019 Witnessing Enormous Growth with Recent Trends & Demand |Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc, SciFluor Life Sciences LLC, ThromboGenics NV  Market Research Tribunal

The global Retinal Vein Occlusion Therapeutics market is comprehensively and Insightful information in the report, taking into consideration various factors such ...

Reviewing Menlo Therapeutics Inc. (MNLO)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  Stocks Beat

Menlo Therapeutics Inc. (NASDAQ:MNLO) and Clearside Biomedical Inc. (NASDAQ:CLSD), both competing one another are Biotechnology companies. We will ...

Specialist shares key messages of Euretina guidelines for management of RVO  Healio

VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, ...

Retinal Vein Occlusion Market Evaluation, Main Competitor and Methods, Regional Outlook, 2019 to 2024  Top 360 News

Retinal Vein Occlusion Market report covers the illness overview, definition, classification, signs, ethology, pathophysiology and diagnostic strategies.

Re-Vana Therapeutics Names Renowned International Experts to Inaugural Scientific Advisory Board  BioSpace

New International Team Brings Extensive Ocular Drug Delivery and Scientific Expertise to Advance the Sustained Release of Biologics and Small Molecules into ...

Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint  GlobeNewswire

Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 -. - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week ...

Retinal Vein Occlusion Therapeutics Market Size: Technological Advancement & Growth Analysis with Forecast to 2025 - Press Release  Digital Journal

The Retinal Vein Occlusion Therapeutics market report includes a comprehensive analysis of the competitive landscape of this vertical.- The report provides an ...

Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9) | Antibodies | News Channels  PipelineReview.com

Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9)

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting  BioSpace

BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma, Inc. (Nasdaq: ARRY) announced that that it will present data from the Phase 3 COLUMBUS ...

Retinal Vein Occlusion Market Report 2019 Top Companies, Sales, Revenue, Forecast and Detailed Analysis  Rochester Leader

This research by 360 Research Reports covers the current market size of the Retinal Vein Occlusion along with the growth rate over the years. In addition to this, ...

Driving licence - Medical conditions you need to tell the DVLA about to avoid £1,000 fine  Express

MOTORISTS must tell DVLA about different medical conditions on their driving licence to avoid landing a fine.

CF Patients at Higher Risk for Retinal Vein Occlusions, Case Report Says  Cystic Fibrosis News Today

A case report suggests that cystic fibrosis patients have a higher risk of retinal vein occlusions as a complication of their pro-inflammatory status.

Global Retinal Vein Occlusion Treatment Market 2019-2023| Strong Pipeline and Recent Drug Approvals to Boost Demand | Technavio  Business Wire

The global retinal vein occlusion treatment market 2019-2023 is expected to post a CAGR of over 9% during the forecast period, according to Technavio.

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:Advanced retinal imaging can improve understanding of retinal vein ...

Global Placenta Growth Factor Market Outlook 2019 – 2025 : Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd, Clearside BioMedical – PortNews24  PortNews24

Global Placenta Growth Factor Market research report offers high-quality insights and in-depth information of Placenta Growth Factor Industry. It provides vital ...

Charming Shoppes Inc (NASDAQ:CHRS) Sentiment Change Report  The MAK Daily

Charming Shoppes Inc (NASDAQ:CHRS) institutional sentiment increased to 1.5 in Q1 2019. Its up 0.21, from 1.29 in 2018Q4. The ratio has improved, as 57 ...

Global Retinal Surgery Devices Market 2019 – Alcon, Bausch Lomb, Iridex, Synergetics USA, ASICO  Exclusive Reporter 24

The Global Retinal Surgery Devices Market Report 2019-2025 includes a comprehensive analysis of the present Retinal Surgery Devices Market. It specifies the ...

Retinal Vein Occlusion Market 2019 Future Scope Demands, CAGR Status and Projected Industry Growths to 2021  The Port Bulletin

Retinal Vein Occlusion Market Report conducts primary and secondary research to derive valuable information on the global Retinal Vein Occlusion market.

Post-marketing surveillance study of the safety of dexamethasone intra | OPTH  Dove Medical Press

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment ...

Reviewing Coherus BioSciences Inc. (CHRS)'s and Five Prime Therapeutics Inc. (NASDAQ:FPRX)'s results  Stocks Beat

Coherus BioSciences Inc. (NASDAQ:CHRS) and Five Prime Therapeutics Inc. (NASDAQ:FPRX) compete with each other in the Biotechnology sector. We will ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Regeneron Pharmaceuticals Inc. (REGN) and Five Prime Therapeutics Inc. (NASDAQ:FPRX) Comparison side by side  Stocks Beat

Both Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Five Prime Therapeutics Inc. (NASDAQ:FPRX) compete on a level playing field in the ...

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer  PRNewswire

BOULDER, Colo., May 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase ...

Cystoid Macular Edema Market Size Incredible Possibilities and Growth Analysis and Forecast To 2025  Digital Day News

Cystoid macular edema (CME) also known as Irvine Gass Syndrome is a painless disorder affecting the central retina or macula. This condition is characterized ...

Regeneron Pharmaceuticals Inc. (REGN)'s Financial Results Comparing With Arvinas Inc. (NASDAQ:ARVN)  Stocks Beat

Both Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Arvinas Inc. (NASDAQ:ARVN) are Biotechnology companies, competing one another. We will ...

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, ...

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Sell” at ValuEngine  Tech Know Bits

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Reviewing Coherus BioSciences Inc. (CHRS)'s and Principia Biopharma Inc. (NASDAQ:PRNB)'s results  Stocks Beat

Both Coherus BioSciences Inc. (NASDAQ:CHRS) and Principia Biopharma Inc. (NASDAQ:PRNB) compete on a level playing field in the Biotechnology industry.

Retinal Vein Occlusion - Pipeline Insight, 2019 - ResearchAndMarkets.com  Business Wire

DUBLIN--(BUSINESS WIRE)--The "Retinal Vein Occlusion - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Comparing of Cue Biopharma Inc. (CUE) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Stocks Beat

Cue Biopharma Inc. (NASDAQ:CUE) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), both competing one another are Biotechnology companies.

Europe's Luxturna approval tops November retina news  Healio

The European Commission's approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November.

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Eylea Market Share 2x more Than Lucentis in WMD and 3x more in DME/DR based on Medicare Claims Analysis  Dexur

Dexur's analysis of medicare claims shows that Eylea (Aflibercept) is being used twice as much as Lucentis (Ranibizumab) for Wet Age-related Macular ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Head to Head Survey: Mateon Therapeutics (OTCMKTS:MATN) vs. Momenta Pharmaceuticals (OTCMKTS:MNTA)  Rockland Register

Mateon Therapeutics (OTCMKTS:MATN) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap medical companies, but which is the better stock?

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Treatment arms for CRVO yield no difference in visual acuity results  Healio

BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or ...

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy  Medscape

The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the ...

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

A Girl Whose Eyes Appear White in Photos  Medscape

A 6-year-old girl was referred to pediatric ophthalmology for a white reflex that was seen in photographs by her parents. Initially, the mother only saw the white ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Global Medical Wide Field Imaging Systems Market Insights 2019 – Industry Overview, Competitive Players & Forecast 2025  Market Industry News

The research study, titled “Global Medical Wide Field Imaging Systems market Research Report 2019,” evaluates the historical performance and the current ...

IND application accepted for Aerie's AR-1105  Healio

The FDA has accepted an investigational new drug application for AR-1105, a treatment candidate for macular edema due to retinal vein occlusion, Aerie ...

TAIWAN LIPOSOME/S (NASDAQ:TLC) versus Its Rivals Critical Survey  Rockland Register

TAIWAN LIPOSOME/S (NASDAQ: TLC) is one of 564 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Comparing of Regeneron Pharmaceuticals Inc. (REGN) and Intec Pharma Ltd. (NASDAQ:NTEC)  The NBO News

As Biotechnology businesses, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Intec Pharma Ltd. (NASDAQ:NTEC), are affected by compare.

Arteriovenous malformation of the iris  The BMJ

BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3699 (Published 20 September 2018) Cite this as: BMJ 2018;362:k3699. Article; Related *content*; Metrics ...

Roche-Genentech sees future for AI in retinal disease prevention  Healio

VANCOUVER, British Columbia — Roche-Genentech is working toward a future in which physician and machine come together to improve outcomes for ...

Clearside Biomedical Inc (CLSD) Receives Consensus Rating of “Hold” from Brokerages  Rockland Register

Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have received an average recommendation of “Hold” from the eleven ratings firms that are currently ...

SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO  Healio

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein ...

Kodiak's investigational anti-VEGF yields positive results  Healio

Kodiak Sciences' drug candidate KSI-301 improved vision, anatomy or both in eight of nine patients with severe diabetic macular edema in a phase 1a trial, ...

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVES:Several imaging modalities have been developed to characterize ...

Three trials show efficacy of suprachoroidal CLS-TA injections for macular edema in uveitis  Healio

FORT LAUDERDALE, Fla. — Three clinical trials demonstrated rapid and sustained reduction of macular edema secondary to noninfectious uveitis in patients ...

Could an eye doctor diagnose Alzheimer's before you have symptoms? Study suggests loss of blood vessels in retina reflect changes in brain health  Science Daily

A study of more than 200 people suggests the loss of blood vessels in the retina could signal Alzheimer's disease.

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Omni Bio Pharmaceutical (OTCMKTS:OMBP) vs. Momenta Pharmaceuticals (OTCMKTS:MNTA) Financial Analysis  Tech Know Bits

Omni Bio Pharmaceutical (OTCMKTS:OMBP) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both medical companies, but which is the superior business ...

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine ...

FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy  BioSpace

FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy - read this article along with other careers information, tips and advice on BioSpace.

FDA hits Regeneron with CRL for Eylea syringe  BioPharma Dive

The Food and Drug Administration issued a Complete Response Letter to Regeneron Pharmaceuticals over its pre-filled syringe for the company's eye drug ...

» Load more